ArticleBMC public health2026
Obesity trajectories based on the European association for the study diagnostic framework and their associations with cardiovascular disease: evidence from two longitudinal cohorts.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundCardiovascular disease (CVD) remains a leading global cause of mortality, with obesity being a major modifiable risk factor. The recent European Association for the Study of Obesity (EASO) framework diagnosed obesity by integrating central adiposity and specific complications, advancing beyond body mass index (BMI) alone. However, the association between longitudinal obesity trajectories defined by this framework and CVD risk is unknown.
methodsWe utilized longitudinal data from the China Health and Retirement Longitudinal Study and the English Longitudinal Study of Ageing. Participants were considered to have obesity if they had a BMI of 30 kg/m2 or higher, or a BMI between 25 and < 30 kg/m2 with waist‑to‑height ratio ≥ 0.5 plus at least one of hypertension, diabetes, arthritis, renal disease, chronic obstructive pulmonary disease, or depression. First, we explored the association between baseline obesity and CVD risk. Second, based on three waves, participants were categorized into five trajectories including no obesity, decreasing obesity, increasing obesity, consistent obesity, and fluctuating obesity. Cox proportional hazards models were used to examine the associations between different obesity trajectories and CVD.
resultsA total of 11,858 participants were included in the study. Compared with those without baseline obesity, participants with baseline obesity had a 36% (hazard ratio [HR]: 1.36, 95% confidence interval [CI]: 1.26–1.47, p < 0.001) increased risk of CVD incidence. Besides, based on 7,154 enrolled participants, we found that compared to the no obesity group, participants with a consistent and increasing obesity trajectory had a 50% (HR: 1.50, 95% CI: 1.30–1.72, p < 0.001) and 34% (HR: 1.34, 95% CI: 1.11–1.62, p = 0.003) higher risk of CVD. In contrast, decreasing and fluctuating obesity trajectories were not significantly associated with CVD risk.
conclusionBased on the novel EASO definition of obesity, our study confirmed that baseline obesity was associated with increased CVD risk. Beyond this, dynamic trajectory analyses revealed that both consistent and increasing obesity trajectories were significantly associated with elevated CVD risk. These findings suggest that in CVD prevention, clinical attention should focus on not only the presence of obesity, but also its dynamic progression over time.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.